U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H13ClFN3
Molecular Weight 325.767
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIDAZOLAM

SMILES

CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=DDLIGBOFAVUZHB-UHFFFAOYSA-N
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula C18H13ClFN3
Molecular Weight 325.767
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Midazolam, previously marketed under the trade name Versed, is a medication used for anesthesia, procedural sedation, trouble sleeping, and severe agitation. Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the γ-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil. Data from published reports of studies in pediatric patients clearly demonstrate that oral midazolam provides safe and effective sedation and anxiolysis prior to surgical procedures that require anesthesia as well as before other procedures that require sedation but may not require anesthesia. The most commonly reported effective doses range from 0.25 to 1 mg/kg in children (6 months to <16 years). The single most commonly reported effective dose is 0.5 mg/kg. Time to onset of effect is most frequently reported as 10 to 20 minutes. The effects of midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications.

CNS Activity

Curator's Comment: Midazolam is a benzodiazepine. It works in the central nervous system (brain) to cause sleepiness, muscle relaxation, and short-term memory loss, and to reduce anxiety.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Midazolam

Approved Use

Midazolam hydrochloride syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam hydrochloride syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HYDROCHLORIDE SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours

Launch Date

1985
Primary
Midazolam

Approved Use

Midazolam HCl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HCl SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours

Launch Date

1985
Primary
Midafresa

Approved Use

Epilepsy

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.7 ng/mL
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.9 ng/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.124 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
126.2 ng × h/mL
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
402.7 ng × h/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
100.935 ng*h/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
103.348 ng*h/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
30 nM*h
2 mg single, oral
dose: 2 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3%
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Other AEs: Nausea, Hypotension...
Other AEs:
Nausea
Hypotension
Sources:
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Disc. AE: Nasal discomfort, Somnolence...
Other AEs: Nasal discomfort, Somnolence...
AEs leading to
discontinuation/dose reduction:
Nasal discomfort (1 patient)
Somnolence (1 patient)
Other AEs:
Nasal discomfort (12.4%)
Somnolence (9.3%)
Sources:
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Other AEs: Hypoxemia, Hypotension...
Other AEs:
Hypoxemia (90 patients)
Hypotension (5 patients)
Sources:
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Other AEs: Somnolence, Headache...
Other AEs:
Somnolence (10%)
Headache (7%)
Dysarthria (2%)
Nasal discomfort (5%)
Throat irritation (2%)
Rhinorrhea (3%)
Lacrimation increased (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Nausea
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Nasal discomfort 1 patient
Disc. AE
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Somnolence 1 patient
Disc. AE
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Nasal discomfort 12.4%
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Somnolence 9.3%
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Hypotension 5 patients
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Hypoxemia 90 patients
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Lacrimation increased 1%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Somnolence 10%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Dysarthria 2%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Throat irritation 2%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Rhinorrhea 3%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Nasal discomfort 5%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Headache 7%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 3.7 uM]
yes [Ki 5.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: INHIBITORS: Coadministration with cimetidine: AUC increase of MDZ=10-102%; diltiazem: AUC increase of MDZ=275%; erythromycin: AUC increase of MDZ=281-341; fluconazole: AUC increase of MDZ=250%; grapefruit juice: AUC increase of 52%; itraconazole: AUC increase of MDZ=240-980%; ketoconazole: AUC increase of MDZ=1490%; ranitidine: AUC increase of MDZ=9-66%. INDUCERS: coadministration with carbamazepine: AUC decrease of MDZ=94%; phenytoin: AUC decrease of MDZ=94%; rifampin: AUC decrease of MDZ=96%;
Page: 11,12
minor
minor
minor
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.
1999 Dec
Anticonvulsants for soman-induced seizure activity.
1999 Mar-Apr
Flumazenil antagonizes midazolam-induced airway narrowing during nasal breathing in humans.
1999 May
A double-blind placebo controlled trial of oral midazolam as premedication before flexible sigmoidoscopy.
1999 Nov
No reduction in the sufentanil requirement of elderly patients undergoing ventilatory support in the medical intensive care unit.
1999 Oct
Myoclonic movements in very low birth weight premature infants associated with midazolam intravenous bolus administration.
1999 Sep
Mice lacking the long splice variant of the gamma 2 subunit of the GABA(A) receptor are more sensitive to benzodiazepines.
2000 Jun
Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons.
2001 Apr
Preparation, premedication, and surveillance.
2001 Feb
[Epileptogenic drugs in anesthesia].
2001 Feb
Propofol as a continuous infusion during cardiopulmonary bypass does not affect changes in serum free fatty acids.
2001 Feb
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison.
2001 Feb
The use of thiopentone/propofol admixture for laryngeal mask airway insertion.
2001 Feb
Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo.
2001 Feb
The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery.
2001 Feb
In situ nasal absorption of midazolam in rats.
2001 Feb 1
[Premedication in ambulatory surgery].
2001 Feb 12
[Premedication for endoscopy].
2001 Feb 2
Intra-nasal midazolam in conscious sedation of young paediatric dental patients.
2001 Jan
Ketamine-midazolam total intravenous anaesthesia for prolonged abdominal surgery.
2001 Jan
[Anesthetic experience of emergency coronary artery bypass graft operation in a patient with cardioamyloidosis].
2001 Jan
[Anesthetic management for mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome].
2001 Jan
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
2001 Jan
Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam.
2001 Jan
S(+)-ketamine for rectal premedication in children.
2001 Jan
A comparison of oral clonidine and oral midazolam as preanesthetic medications in the pediatric tonsillectomy patient.
2001 Jan
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam for childhood seizures at home preferred to rectal diazepam.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Safety is as important as efficacy.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Caution is required in applying hospital based evidence to primary care population.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam.
2001 Jan 13
A retrospective study on the effectiveness of intranasal midazolam in pediatric burn patients.
2001 Jan-Feb
Synergistic analgesic effects of intrathecal midazolam and NMDA or AMPA receptor antagonists in rats.
2001 Mar
Selective spinal anesthesia for outpatient laparoscopy. II: epinephrine and spinal cord function.
2001 Mar
Drugs and syringe drivers: a survey of adult specialist palliative care practice in the United Kingdom and Eire.
2001 Mar
Anaesthetic technique for transoesophageal echocardiography in children.
2001 Mar
The effect of anxiety and personality on the pharmacokinetics of oral midazolam.
2001 Mar
Management of background pain and anxiety in critically burned children requiring protracted mechanical ventilation.
2001 Mar-Apr
Burn patients' pain and anxiety experiences.
2001 Mar-Apr
Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery.
2001 May
Characterization of discriminative stimulus effects of the neuroactive steroid pregnanolone.
2001 May
Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.
2001 May
Patents

Sample Use Guides

Midazolam hydrochloride syrup is indicated for use as a single dose (0.25 to 1 mg/kg with a maximum dose of 20 mg) for preprocedural sedation and anxiolysis in pediatric patients. Midazolam hydrochloride syrup is not intended for chronic administration.
Route of Administration: Oral
In Vitro Use Guide
Midazolam (1 uM) decreased GABA-activated currents in acutely dissociated neurons, isolated from the medial septum/nucleus of the diagonal band (MS/nDB) of the adult rat brains.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:03 GMT 2023
Edited
by admin
on Fri Dec 15 15:48:03 GMT 2023
Record UNII
R60L0SM5BC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIDAZOLAM
EP   INN   JAN   MART.   MI   USP   VANDF   WHO-DD  
INN  
Official Name English
Midazolam [WHO-DD]
Common Name English
MIDAZOLAM [EP MONOGRAPH]
Common Name English
MIDAZOLAM [MI]
Common Name English
USL-261
Code English
MIDAZOLAM [MART.]
Common Name English
midazolam [INN]
Common Name English
MIDAZOLAM CIV [USP-RS]
Common Name English
4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-(2-FLUOROPHENYL)-1-METHYL
Common Name English
MIDAZOLAM [USP MONOGRAPH]
Common Name English
MIDAZOLAM CIV
USP-RS  
Common Name English
NAYZILAM
Brand Name English
MIDAZOLAM [ORANGE BOOK]
Common Name English
MIDAZOLAM [JAN]
Common Name English
MIDAZOLAM [VANDF]
Common Name English
DORMICUM
Brand Name English
USL261
Code English
8-CHLORO-6-(2-FLUOROPHENYL)-1-METHYL-4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE
Systematic Name English
Classification Tree Code System Code
DEA NO. 2884
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
WHO-VATC QN05CD08
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 514115
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
LIVERTOX NBK548691
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 373912
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 1.3
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 622817
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 507615
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
NCI_THESAURUS C1012
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 217405
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
WHO-ATC N05CD08
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
NDF-RT N0000175694
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 508215
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
FDA ORPHAN DRUG 277809
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID5023320
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
RXCUI
6960
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY RxNorm
RS_ITEM_NUM
1443599
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
INN
4497
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
WIKIPEDIA
MIDAZOLAM
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
CHEBI
6932
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
DAILYMED
R60L0SM5BC
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
NCI_THESAURUS
C62049
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
MESH
D008874
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
EVMPD
SUB08950MIG
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
CAS
59467-70-8
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
LACTMED
Midazolam
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
ECHA (EC/EINECS)
261-774-5
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
DRUG BANK
DB00683
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
MERCK INDEX
m7531
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY Merck Index
IUPHAR
3342
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
CHEBI
6931
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
PUBCHEM
4192
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
ChEMBL
CHEMBL655
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
CHEBI
7581
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
HSDB
6751
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
SMS_ID
100000080626
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
FDA UNII
R60L0SM5BC
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
DRUG CENTRAL
1802
Created by admin on Fri Dec 15 15:48:04 GMT 2023 , Edited by admin on Fri Dec 15 15:48:04 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC